FUSEN PHARM (01652.HK): Piracetam Injection Approved for Marketing, Market Size Exceeds RMB250 Million in 2025
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) announced that the marketing application for Piracetam Injection developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has been approved by the National Medical Products Administration (NMPA). The product is indicated for memory impairment and mild to moderate cerebral dysfunction caused by acute and chronic cerebrovascular diseases, brain trauma and toxic encephalopathy, and also for mental retardation in children. Piracetam Injection is a Class B drug covered by the National Medical Insurance Catalogue, with domestic sales exceeding RMB250 million in 2025.
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) released a voluntary announcement on 16 June 2026. The marketing application for Piracetam Injection developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has obtained approval from the National Medical Products Administration. It is applicable to memory decline and mild-to-moderate cerebral dysfunction induced by acute and chronic cerebrovascular disorders, brain injury and toxic encephalopathy, as well as childhood intellectual developmental delay.
Piracetam Injection is a cerebral metabolism-improving agent, the first racetam-class drug developed based on the structure of inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It activates adenylate kinase, raises the cerebral ATP/ADP ratio, boosts cerebral absorption and utilisation of amino acids, proteins and glucose, accelerates cerebral cell metabolism and elevates the cerebral cortex’s hypoxia resistance. In addition, in vitro tests verify that piracetam can protect mitochondria against oxidative stress and other damages.
Piracetam is recommended for Alzheimer’s disease treatment in theChinese Guidelines for the Diagnosis and Management of Dementia and Cognitive ImpairmentandExpert Consensus on Diagnosis and Treatment Procedures for Cognitive Impairment in the Elderly in China; it is included in theChinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Strokefor neuroprotection, and listed as a recommended drug under theExpert Consensus on Clinical Management of Post-Stroke Aphasia.
This product is categorised as a Class B reimbursable drug under the National Medical Insurance Catalogue. According to Menet data, sales of Piracetam Injection across China’s three major medical terminals and six segmented markets surpassed RMB250 million in 2025. The Group’s Piracetam Injection in the specification of 20ml:8mg has been commercially available in China for years. Two additional specifications approved concurrently this time, namely 5ml:1mg and 15ml:3mg, can satisfy diverse treatment demands of patients.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
